194 related articles for article (PubMed ID: 11698762)
1. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
Gupta P; Gokhale R; Kirschner BS
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):450-4. PubMed ID: 11698762
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
Dubinsky MC; Lamothe S; Yang HY; Targan SR; Sinnett D; Théorêt Y; Seidman EG
Gastroenterology; 2000 Apr; 118(4):705-13. PubMed ID: 10734022
[TBL] [Abstract][Full Text] [Related]
3. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Goldenberg BA; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2004 Sep; 99(9):1744-8. PubMed ID: 15330913
[TBL] [Abstract][Full Text] [Related]
4. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Cuffari C; Hunt S; Bayless T
Gut; 2001 May; 48(5):642-6. PubMed ID: 11302961
[TBL] [Abstract][Full Text] [Related]
5. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
6. Mercaptopurine metabolite results in clinical gastroenterology practice.
Bloomfeld RS; Onken JE
Aliment Pharmacol Ther; 2003 Jan; 17(1):69-73. PubMed ID: 12492734
[TBL] [Abstract][Full Text] [Related]
7. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.
Ooi CY; Bohane TD; Lee D; Naidoo D; Day AS
Aliment Pharmacol Ther; 2007 Apr; 25(8):941-7. PubMed ID: 17402998
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
[TBL] [Abstract][Full Text] [Related]
10. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
Derijks LJ; de Jong DJ; Gilissen LP; Engels LG; Hooymans PM; Jansen JB; Mulder CJ
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
[TBL] [Abstract][Full Text] [Related]
11. 6-MP metabolite levels: a potential guide to Crohn's disease therapy.
Sandborn WJ
Gastroenterology; 1997 Aug; 113(2):690-2. PubMed ID: 9247497
[No Abstract] [Full Text] [Related]
12. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.
Achkar JP; Stevens T; Easley K; Brzezinski A; Seidner D; Lashner B
Inflamm Bowel Dis; 2004 Jul; 10(4):339-45. PubMed ID: 15475740
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
Thomas CW; Lowry PW; Franklin CL; Weaver AL; Myhre GM; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
Inflamm Bowel Dis; 2003 Jul; 9(4):237-45. PubMed ID: 12902847
[TBL] [Abstract][Full Text] [Related]
14. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Cuffari C; Théorêt Y; Latour S; Seidman G
Gut; 1996 Sep; 39(3):401-6. PubMed ID: 8949645
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche J; Desager JP; Horsmans Y; Louis E
Scand J Gastroenterol; 2001 Jan; 36(1):71-6. PubMed ID: 11218242
[TBL] [Abstract][Full Text] [Related]
16. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting.
Mardini HE; Arnold GL
J Clin Gastroenterol; 2003; 36(5):390-5. PubMed ID: 12702978
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
Nguyen TV; Nguyen TM; Lachaux A; Boulieu R
J Clin Pharmacol; 2013 Sep; 53(9):900-8. PubMed ID: 23856979
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Spencer E; Norris E; Williams C; Dubinsky MC
Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
[TBL] [Abstract][Full Text] [Related]
19. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells.
Lennard L; Maddocks JL
J Pharm Pharmacol; 1983 Jan; 35(1):15-8. PubMed ID: 6131958
[TBL] [Abstract][Full Text] [Related]
20. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
